Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | EIF4E | P06730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17492798 | 0.90 | BRD4 (0.49) | BRD4PIK3C3 | |
| SCHEMBL17492703 | 0.88 | BRD4 (0.55) | BRD4 | |
| SCHEMBL20412185 | 0.86 | BRD4 (0.46) | BRD4 | |
| SCHEMBL17492637 | 0.85 | BRD4 (0.49) | BRD4 | |
| SCHEMBL17492582 | 0.84 | BRD4 (0.49) | BRD4 | |
| SCHEMBL17492759 | 0.83 | BRD4 (0.48) | BRD4 | |
| SCHEMBL17492635 | 0.83 | BRD4 (0.47) | BRD4PIK3C3 | |
| SCHEMBL15771835 | 0.83 | BRD4 (0.62) | BRD4 | |
| SCHEMBL17492826 | 0.83 | BRD4 (0.57) | BRD4 | |
| SCHEMBL17492632 | 0.82 | BRD4 (0.51) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2970330-B1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | ABBVIE INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | BRD1, BRD3, BRD4 | BRD4 3/4885BTK 164/4885PIK3C3 2124/4885 |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885BTK 795/4885PIK3C3 1975/4885 |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885BTK 795/4885PIK3C3 1975/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885BTK 795/4885PIK3C3 1975/4885 |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885BTK 917/4885PIK3C3 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.